CLINICAL_TRIALS
trial_result
· 2018-10-02
Clinical Trial Update: Open-Label Phase 3 Long-Term Safety Study of Migalastat [Phase 3]
Summary
Open-label Phase 3 long-term safety study of migalastat in Fabry disease was terminated; results posted in 2018.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amicus Therapeutics | Conditions: Fabry Disease | Phase 3 | Status: TERMINATED | Results posted: 2018-10-02